| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.0034 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.0046 | 0.9 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | PF-562271 | GDSC1000 | pan-cancer | AAC | 0.0028 | 0.9 |
| mRNA | JQ-1:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.0028 | 0.9 |